Pharmaceutical Company - Targeting Drug Delivery

Our client operates a lean, high-margin B2B lead-generation platform dedicated to the Internet of Things sector. By leveraging a permission-based community of over 60,000 vetted IoT decision-makers and a LinkedIn Group of 20,000+ approved professionals, they deliver turnkey sponsored webinars, white-paper campaigns, and targeted email blasts—providing technology vendors with consistently qualified leads while maintaining minimal overhead through a fully remote, contractor-driven model. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

This profitable Company is a unique California medical network that can be customized to the needs of each individual client. The Company has years of experience in PPO. The business model generates recurring revenue and the technology allows the subscribing clients to customize the network to fit their own needs. The Company also offers several re-pricing options to payers. The Company reviews provider performance to assure compliance with the network's evidence-based treatment guidelines, improving outcomes and offers metrics germane to the medical treatment within the network, allowing payers to monitor performance. The Company is a resource for Group Medical Insurance Providers and Payers, and for Workers Comp Payers to create a custom network of highly qualified medical providers, specific to California. The Company's network and technology allow Payers and Employers to tailor their network to their own specific needs. The payers subscribe to the Company's network generating recurring revenue for the Company. NOTE: This is a re-listing of a major purchase opportunity for a rapidly expanding, profitable California medical network. The initial response to the original listing of this opportunity was huge. A large investment group signed a Letter of Intent To Purchase early on, thus removing the opportunity from the marketplace. The holder of the LOI, following numerous delays over many months, was unable to proceed due to unexpected internal problems separate from their signing the LOI or their completed due diligence. Therefore, this terrific opportunity is now again available for purchase. Our Client's business and profits continue to expand. They have re-listed this purchase opportunity at $3M (USD). This sale price, based on current revenues, growth and profits, should be recovered by a Buyer in short order. Please do not respond to this opportunity unless you will provide proof of funds prior to any demos or negotiations; i.e. the capability to make an acquisition of $3M dollar (USD). The Seller only wishes to work with interested Buyers who, once they are satisfied with their due diligence, are prepared to proceed immediately. We do ask for your understanding in these regards as our initial listing generated a very high volume of responses. NDA is required to secure first round of comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Facilities: Current rent is $1975 per month for the 1050 sq ft space. Many staff currently work from home, and some have remained in the office space in Tracy, California. Current lease extends through January 31, 2021, so the Buyer may choose to keep this office space or move the Business. The current space allows for social distancing and COVID compliance for those staff who continue to work in the office and not from home. Competition: This Company is unique in the industry and competes against large national players. The Company beats the competition by providing a higher level of customer service, customization of medical provider networks, and competes on price. Growth & Expansion: The Sellers have grown the business to its current level with a slim 'guerilla' marketing budget. An ideal Buyer would have a budget for marketing and advertising, as well as for staffing to handle more leads. With the right Buyer, this Company is primed to grow! Support & Training: As needed. Financing: Available with the right offer Reason for Selling: Retirement.

This is in the presentation of a well-established high-performance gear and bag company for First Responders - Fire, Police, and EMS professionals. The strongly established foundation that is being sold due to changes and personal circumstances has strong profit margins with a steady and repeatable process for income including an opportunity for growth; very little marketing spending and strong word of mouth and organic growth. Key Investment Considerations: * There is No other Company that is offering a similar service essentially in a league all of their own * Nearly all income is from repeat business where they have been able to sustain and grow only through word-of-mouth marketing * Owner is a former Fireman who knows, understands, and has built to spec the items for professionals within Police, Fire, and EMTs which can withstand heavy wear and tear * By using subcontractors so that products are built to spec and offer the highest quality to the professionals in these spaces * Once a client is turned on to these products, they are in essence a client for life * The Company uses only top-tier materials and a proprietary process for assembly ensuring a lifetime warranty on all products * High-quality workmanship and products that are built to last * With their established marketplace and strong clientele what is needed at this point in time is a directed marketing effort With proper marketing and pursuant to bidding on available contracts there are massive growth opportunities available to a new owner considering reputation and company processes. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Facilities: Not available, would need new Company location. Competition: Yes, however processes have been able to in a number of ways keep the Company ahead of the competition. Growth & Expansion: Abundant growth opportunities; little to no marketing up to this point, the flip of a switch, and the company can experience significant growth in the years to come. Financing: Depending on offer and structure may be acceptable. Support & Training: As needed. Reason for Selling: Personal Reasons - Retirement

Our client is offering a next generation, patented medical device for the treatment of internal hemorrhoids. The procedure is painless, non-invasive, requires no anesthesia, is conducted in under 2 minutes, and can be performed in any medical setting: a doctor's office, a surgery center, an endo suite, or a hospital. Our client's product is a small, disposable, medical device that eliminates hemorrhoids. A physician uses this device by deploying a tiny rubber band on the base of the hemorrhoid. This procedure is known as rubber band ligation, and it is the #1 recommended treatment for internal hemorrhoids by the American College of Gastroenterology. Patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. The device is currently manufactured in the USA through an FDA approved, ISO 13485 contract manufacturer, who specializes in medical devices. The device is sold directly to physicians of different specialties, including gastroenterologists, colorectal surgeons, GYNs, urologists and primary care physicians. The biggest targeted audience are gastroenterologists. NDA is required to secure comprehensive Confidential Information Memorandum. Growth and epansion: Nearly half of adults over the age of 50 will develop symptomatic hemorrhoids. In the U.S. alone, an estimated 60,000,000 people have experienced hemorrhoid symptom(s) at some point in their lives. Annually, over 20,000,000 people in the U.S. use an over-the-counter hemorrhoid treatment and 75% report a reoccurrence. These patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. Financing is if the price and deal structure is right, and support and training is provided as required. Facilities are Outlined in CIM. Reason for selling is that the owners wish to move on to other projects.

Founded in 2011, the Company is a niche consulting and advisory firm serving in cell therapy, gene and gene-modified cell therapies, other regenerative medicines, tissue engineering, and cell-based drug discovery. The company's core focus is to improve cell & gene therapy innovations by providing consulting services for improving business strategy and achieving major regulatory milestones for companies. The Company has created a one-stop shop for all aspects of cell therapy and gene therapy, including quality checks, regulatory meetings, and submissions with the help of leading experts worldwide. The leadership has a unique combination of experience in the academic, biotech industry, government/FDA, and consulting. They serve biotech, pharma companies, consulting services for healthcare providers, subcontracts for other consulting firms, and contracts with government organizations, which enables them to have 6x+ growth in net income from 2019 2021, i.e., $179,000 to $1,095,000 with the help of 110+ customers served over the past six years. The Company's plan is to consummate a transaction with a supportive growth partner in order to accelerate the company's cell and gene therapy market growth by interacting with industry, academia, government, and other international stakeholders in cell & gene therapies and cell-based drug discovery. NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: Has headquarters in US contractors operate nationwide / portable / buyer can be located worldwide. Competition: A few competitors in the space are in the field but the Company provides best in class services for its respective niche(s). Growth & Expansion: Continually grow and become more profitable with the help of experts that supports preclinical, clinical, and commercial advisory in the manufacturing, regulatory affairs, Quality/GxP, and M&A arenas. Financing: If the price and deal structure is right. Support & Training: Long term transition, Seller wishes to smooth the transition to maximize success with the Company post-closing and spearhead continued growth. Reason for Selling: Growth.

Our client is an exploding, music talent agency--yearly revenue has increased since inception, at a percentage rate year over year of approximately 600%. Our client is a 'positive hustle and hard work ethic' music talent business built on the sheer effort of bringing music artists to the performance stage. Built from the ground up, the business foundation has been developing emerging performance talent while using well-known artists to kick in larger revenue when possible. A great source of success has come from acquiring visas for in-demand international artists and bringing them to the US marketplace. Our client brings the following: - 80+ acts signed to exclusive contracts (1-to-2-year terms) - Robust artist scouting protocol signing on average 3 acts a week - Can be staffed with agents anywhere in the world - Access to the nation's largest contact book of venues, talent buyers, and promoters - Non-exclusive booking rights for Snoop Dogg, Ice Cube, OT Genasis, Xzibit, Warren G, Bizzy Bone, B.o.B, and Bone Thugs N Harmony - Over 1,000 performances booked in half of a calendar year (2022) - Artists in several genres are actively leaving their current booking agencies in favor of coming onto our client's roster. Our client has been awarded positive recognition by a large majority of its artists as well as publications like MoneyGeek, DMC World, Pollstar, Gigwell, and Shoutout Atlanta. The Company's key paradigm is to find and monetize talent. Our client's team is constantly scouting new talent locally and internationally and bringing them to the marketplace. Our client consults on all aspects of artist growth from graphic design and social media strategy to music guidance and consulting. Urgency drives the foundations and operations of Our client's enterprise. This has proven to be a successful strategy, as month over month, our client is showing exceptional growth: in 2022 up to July, the Company is averaging $86,500 per month in gross revenue. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Growth/Expansion: In CIM. Financing: Seller does not wish to finance. Support & Training: Provided at no charge to enable a smooth transition. Reason for Selling: other projects.

Our client is a world leader in iris recognition technology with a large production capacity based in USA. They are a multinational corporation with a robust track record of selling its best-selling, award winning technology products worldwide. Clients include the UN, the US Department of Homeland Security, US Navy, US Marine Corps, the governments of India the Philippines, Kenya, and in the private Sector Northrop Grumman, InCadence and numerous others. The company has and continues to develop an ever-increasing range of technical applications for its products in a very large and rapidly growing market. Applications range from numerous physical security applications to blockchain and cryptocurrency applications. This firm owns 28 patents (24 registered and 4 pending) for its proprietary "iris matching algorithm, iris recognition in bright outdoors under sunlight" technology and security technology. Our client also has world-leading iris recognition technology to crypto wallet, which dramatically improves the security and convenience of digital assets on blockchain. In addition to multiple patents, our client also owns 10 trademarks. Our client's iris recognition algorithm was evaluated as the world's best technology at IREX I of NIST in the USA, and its excellence has been proven. They are one of few companies to provide a complete solution including SW and HW from iris image scanner to matching SDK on server with the world's best technology. This business has global references for the National ID projects of the Indian and Philippine governments They achieved the No.1 market share, including UN-affiliated organizations such as UNHCR and WFP, and these markets are expanding worldwide. Our client's tech and related device is the only iris camera system satisfying MOSIP SBI 2.0 requirements for authentication (many countries are utilizing the MOSIP platform for their National ID systems). Our client's unique and powerful technologies are registered and protected by global patents, enabling stable business development and expansion. The company offers a total data infrastructure solution (large or small data requirements) for Web 3.0 (Web 3.0 is the approach for a new iteration of the World Wide Web which incorporates concepts such as decentralization, blockchain technologies, and token-based economics). Their technologies are based on Blockchain, IPFS, and distributed storage of private keys (IPFS is a distributed file system that seeks to connect all computing devices with the same system of files. This means data can be securely shared for Know Your Customer and Anti-Money Laundering (KYC and AML) needs. This meets information sharing protocols between service providers and will lead to a new and open data economy. The ramifications are complete security for Bank information, Financial Transaction Data, Driving Data, SNS Contents, Health Information, Government/Education Certification, Insurance Information in short data stemming from virtually any source. Confidential Information Memorandum (CIM) is available upon receipt of our short online NDA. Financing: If the price and deal structure is right. Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: World-wide expansion

The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A very low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. Existing collaborations with major manufacturers coupled with a current expedited approval process with the FDA presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500k to $1M to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could utlimately yield the balance of funding to fully deploy a commercial version of the technology. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by us. Detailed Information Competition: No current option available besides bed rest. Growth & Expansion: Huge market potential. Support & Training: Full team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .